Physician profile
Casey Orzechowicz
NPI 1073074597
$14,613.62
in general payments reported to CMS, 2019-2025
30 companies · $4,935 in 2025
The $4,935 reported for 2025 was more than what 93% of Pain Medicine (Anesthesiology) providers received nationally (typical 2025 total: $458).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $44.15 · 2020: $13.60 · 2021: $135 · 2022: $275 · 2023: $2,724 · 2024: $6,488 · 2025: $4,935.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,982 · Travel and Lodging: $5,165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,981.70 |
| Travel and Lodging | $5,164.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $5,963.29 | 2021-2025 | Kyphon Express II Kyphopak Tray, Intellis Adaptivestim, Synchromedii |
| Abbott Laboratories | $3,014.42 | 2023-2025 | Eterna, Proclaim |
| Boston Scientific Corporation | $2,936.36 | 2022-2025 | Wavewriter Alpha Prime 16 |
| Pfizer INC. | $280.14 | 2024-2025 | |
| Collegium Pharmaceutical, INC. | $278.18 | 2024-2025 | Xtampza, Belbuca |
| Abbvie INC. | $227.20 | 2024-2025 | |
| Ucb, INC. | $219.87 | 2025 | Zilbrysq, Nayzilam, Briviact |
| Lundbeck LLC | $211.90 | 2024-2025 | Vyepti |
| Nevro Corp. | $173.40 | 2024 | Senza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $153.65 | 2023-2024 | Relistor |
| Neurelis, INC. | $144.24 | 2024-2025 | Valtoco |
| Csl Behring | $119.48 | 2024-2025 | Hizentra |
| Pacira Pharmaceuticals Incorporated | $87.94 | 2023 | Exparel |
| Alexion Pharmaceuticals, INC. | $87.80 | 2024-2025 | Ultomiris |
| Merck Sharp & Dohme LLC | $86.06 | 2019-2023 | Bridion |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $74.84 | 2025 | Uplizna |
| Eisai INC. | $65.28 | 2024-2025 | |
| Globus Medical, INC. | $57.78 | 2025 | Senza |
| Teva Pharmaceuticals USA, INC. | $55.34 | 2025 | Ajovy |
| Lilly USA, LLC | $53.87 | 2025 | Kisunla |
| Neurocrine Biosciences, INC. | $49.43 | 2025 | |
| Sk Life Science, INC. | $39.91 | 2025 | |
| Acadia Pharmaceuticals INC | $36.41 | 2024 | Nuplazid |
| Takeda Pharmaceuticals U.S.A., INC. | $34.78 | 2025 | Hyqvia |
| Vertex Pharmaceuticals Incorporated | $34.30 | 2025 | |
| Averitas Pharma INC. | $30.37 | 2023-2025 | Qutenza |
| Axsome Therapeutics, INC. | $27.40 | 2025 | Symbravo |
| Avanos Medical | $26.35 | 2024 | Coolief* Cooled Radiofrequency |
| Tonix Medicines, INC. | $26.20 | 2025 | Tonmya |
| Scilex Pharmaceuticals INC. | $17.43 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Casey Orzechowicz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.